Zepteon, Inc., founded in 2012, is a privately held company specializing in the development of advanced chromatography resins. These resins are designed to separate antibodies and Fc-fusions with specific glycoforms, enhancing their potency against infectious diseases, cancer, autoimmunity, and rare diseases. Zepteon's core mission is to innovate and provide technologies that facilitate the research, development, and production of transformative medicines, thereby improving therapeutic outcomes.
Notable figures associated with Zepteon include its founders and key investors who have supported the company's pioneering efforts in biotechnology. The company has achieved significant milestones in developing first-in-class chromatography resins that are crucial for the pharmaceutical industry. Zepteon's impact is evident in its contribution to more effective therapeutic solutions, positioning it as a leader in the field of antibody separation technology.
